SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-038611
Filing Date
2020-11-23
Accepted
2020-11-20 21:42:24
Documents
3
Period of Report
2020-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea130308-8k_aditxtherap.htm 8-K 35884
2 CONSULTING AGREEMENT, DATED NOVEMBER 18, 2020 ea130308ex10-1_aditxtherap.htm EX-10.1 156349
3 PRESS RELEASE, DATED NOVEMBER 19, 2020 ea130308ex99-1_aditxtherap.htm EX-99.1 7748
  Complete submission text file 0001213900-20-038611.txt   201306
Mailing Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043
Business Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043 909-488-0844
Aditx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 201334144
SIC: 2834 Pharmaceutical Preparations